Unicycive Therapeutics Inc.
13F holders, Q1 2024 (March 31)23holders
2famous investors
$1.49avg. 13F price*
At the end of Q1 2024, 23 institutions reported holding Unicycive Therapeutics Inc. in their 13F filings. The largest holders were Nantahala Capital Management, LLC ($8.6M), BVF Inc. ($5.0M) and Ra Capital Management, L.P. ($4.8M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Unicycive Therapeutics Inc.
- CUSIP
- 90466Y103
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $7.1M |
| Exits | 0 | $0 |
Ownership 23 holders
| Nantahala Capital Management, LLC | 0.85% | Reduce -3.0% | 3,335,586 | $8.6M |
| BVF Inc. | 0.14% | Add +70.5% | 3,611,601 | $5.0M |
| Ra Capital Management, L.P. | 0.06% | No change | 3,470,688 | $4.8M |
| Vivo Capital, LLC | 0.38% | No change | 3,470,152 | $4.8M |
| Logos Global Management LP | 0.32% | New | 3,469,927 | $3.0M |
| Rosalind Advisors, Inc. | 2.43% | New | 1,879,646 | $2.6M |
| Monashee Investment Management LLC | 0.17% | New | 1,000,000 | $1.4M |
| Vanguard Group Inc. | 0.00% | Add +195.4% | 339,860 | $469K |
| Geode Capital Management, LLC | 0.00% | Add +49.7% | 253,193 | $349K |
| Goldman Sachs Group Inc. | 0.00% | Reduce -0.0% | 93,339 | $129K |
| Renaissance Technologies | 0.00% | Add +172.4% | 92,860 | $128K |
| Citadel Advisors | 0.00% | Add +95.9% | 69,395 | $96K |
| State Street Corp. | 0.00% | No change | 35,036 | $48K |
| Virtu Financial LLC | 0.00% | New | 26,082 | $36K |
| Northern Trust Corp. | 0.00% | New | 23,998 | $33K |
| Ground Swell Capital, LLC | 0.03% | New | 19,118 | $26K |
| Captrust Financial Advisors | 0.00% | No change | 18,800 | $26K |
| Tandem Capital Management Corp. | 0.01% | No change | 15,500 | $21K |
| Integrated Wealth Concepts LLC | 0.00% | No change | 10,000 | $14K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +13.6% | 7,678 | $11K |
| UBS Group AG | 0.00% | Add +2392.6% | 4,387 | $6K |
| Wells Fargo & Company | 0.00% | Add +1.6% | 196 | $270 |
| JPMorgan Chase & Co. | 0.00% | New | 47 | $65 |
"% of holder's portfolio" is UNICYCIVE THERAPEUTICS INC's weight in each manager's 13F, not the share of Unicycive Therapeutics Inc. the manager owns.